Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytomx Thera (NQ: CTMX )

1.620 +0.050 (+3.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 941,366
Open 1.610
Bid (Size) 1.600 (3)
Ask (Size) 1.750 (5)
Prev. Close 1.570
Today's Range 1.520 - 1.650
52wk Range 1.505 - 8.340
Shares Outstanding 65,392,758
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
CytomX Therapeutics Initiates Dosing in Early-Stage Study Of Solid Tumor Settings
CytomX Therapeutics, Inc. (NASDAQ: CTMX) initiated enrolment by dosing first patient in a Phase 1 dose-escalation study of CX-904 for patients with advanced solid tumors. 
Via Benzinga
CytomX Therapeutics: Q1 Earnings Insights
CytomX Therapeutics (NASDAQ:CTMX) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:15 PM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-63.92%
-63.92%
1 Month
-10.50%
-10.50%
3 Month
-59.80%
-59.80%
6 Month
-76.00%
-76.00%
1 Year
-80.22%
-80.22%

More News

Read More
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Earnings Scheduled For March 1, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
41 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Via Benzinga
CytomX Therapeutics: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Rite Aid Shares Spike Higher
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
Via Benzinga
55 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 3%; Aldeyra Therapeutics Shares Slide
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
CytomX Posts Interim Data From Phase 2 Trial Of CD71-Targeting Cancer Candidate
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
26 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.